ALC Stock Rises Following the Merger Agreement With LENSAR
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?
ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.
Alcon Stock Gains From Innovation Despite Macroeconomic Troubles
Within Vision Care, ALC is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
Watch CNBC's full interview with Alcon CEO David Endicott
Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results.
Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript
Alcon Inc. (NYSE:ALC ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Jeff Johnson - Baird Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Julien Ouaddour - Bank of America Patrick Wood - Morgan Stanley David Adlington - JPMorgan Brett Fishbin - Keybanc Capital Markets Harry Shrives - Citi Tom Stephan - Stifel Issie Kirby - Redburn Atlantic Kavya Deshpande - UBS Jack Reynolds-Clark - RBC Capital Markets Chris Pasquale - Nephron Research LLC Anthony Petrone - Mizuho Group Michael Sarcone - Jefferies Operator Greetings, and welcome to the Alcon Fourth Quarter and 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours
ALC's performance is driven by robust demand for its innovative products, balanced geographic footprint and strong execution by the team.
Alcon eyes revenue growth in 2025 after in-line results
Alcon forecast sales of between $10.2 and $10.4 billion for 2025, after the eye care group reported higher fourth-quarter revenue underpinned by its surgical division on Tuesday.
Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings
Evaluate the expected performance of Alcon (ALC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here's Why Alcon (ALC) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Needham ups Alcon target, adds to Conviction List
Needham earlier today raised the firm's price target on Alcon (ALC) to $108 from $103 and kept a Buy rating on the shares. The firm also added the stock to its Conviction List, replacing RxSight (RXST). Alcon's product launch lineup is one of the best it's been since its spin from Novartis, the analyst told investors in a research note. Needham expects the product launches to result in Alcon's revenue growth accelerating throughout 2025, which should drive multiple expansion. The firm made the stock a top pick for 2025. With the stock's valuation meaningfully below Alcon's historical range, risks around currency and commercial investments are baked in, making the risk/reward attractive, contended Needham. Alcon +1.88 (+2.24%) RxSight -0.1 (-0.26%)
Reasons to Retain Alcon Stock in Your Portfolio for Now
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
